“Human Leukocyte B site 5801 Gene Detection Kit(PCR-Fluorescence Method)”has obtained the registration certificate of Class III from NMPA. After SLCO1B1&APOE, CYP2C19, MTHFR, ALDH2, CYP2C9&VKORC1 and Hypertension gene testing products, this is another Class III certificate of pharmacogenomics.
We will continue to uphold a responsible attitude towards the industry, establish industry benchmarks with high-quality products, and lead the common development of pharmacogenomics!
Product Characteristics:
This kit is suitable for in vitro qualitative detection of Human Leukocyte B site 5801 Gene Detection Kit(PCR-Fluorescence Method) in human whole blood sample DNA. It is used for clinical auxiliary diagnosis and for personalized medicine reference.
Product Advantages:
① Easy operation
② Open kit
③ Simple to judge
④High specificity
⑤ Anti-pollution system
Product application scenarios:
1.People using allopurinol drugs
2.Application department: rheumatology, endocrinology and all departments using allopurinol drugs.
Background on the use of allopurinol:
Allopurinol, a first-line drug for the treatment of gout, is a xanthine oxidase inhibitor used primarily as an adjunctive therapy for the treatment of gout and the prevention of gouty nephropathy, secondary hyperglycemia, and severe epilepsy. However, the drug can cause serious cutaneous adverse reactions (SCARs) such as hypersensitivity syndrome (HSS), Stevens-Johnson syndrome (SJS), and toxic epidermal electrolysis-relaxation (TEN).
Numerous studies at home and abroad have shown a strong correlation between the HLA-B*5801 allele and allopurinol-induced severe cutaneous adverse reactions, and the Chinese population (especially Han population) carries this allele with a high frequency (10-20%). American College of Rheumatology Management Gout Management Guidelines recommend that the tests of HLA-B*5801 should be performed on people at high risk for severe allergic reactions (Han Chinese, Korean, Thai, etc.) in 2021.
